Editorial
doi: 10.3324/haematol.2009.016865.
Molecular basis of juvenile myelomonocytic leukemia
- PMID: 20139388
- PMCID: PMC2817017
- DOI: 10.3324/haematol.2009.016865
Item in Clipboard
Editorial
Molecular basis of juvenile myelomonocytic leukemia
Haematologica.
2010 Feb.
No abstract available
Figures
Diagnostic criteria of juvenile myelomonocytic leukemia.
RAS-RAF-MEK-ERK signaling pathway.
Comment on
-
Mitotic recombination and compound-heterozygous mutations are predominant NF1-inactivating mechanisms in children with juvenile myelomonocytic leukemia and neurofibromatosis type 1.Haematologica. 2010 Feb;95(2):320-3. doi: 10.3324/haematol.2009.010355. Epub 2009 Dec 16. Haematologica. 2010. PMID: 20015894 Free PMC article.
Similar articles
-
[Myelodysplastic syndrome in children].Rinsho Ketsueki. 2009 Oct;50(10):1560-9. Rinsho Ketsueki. 2009. PMID: 19915367 Review. Japanese. No abstract available.
-
Gene mutations in the Ras pathway and the prognostic implication in Korean patients with juvenile myelomonocytic leukemia.Ann Hematol. 2012 Apr;91(4):511-7. doi: 10.1007/s00277-011-1326-9. Epub 2011 Sep 8. Ann Hematol. 2012. PMID: 21901340
-
CBL mutations in juvenile myelomonocytic leukemia and pediatric myelodysplastic syndrome.Leukemia. 2010 May;24(5):1090-2. doi: 10.1038/leu.2010.49. Epub 2010 Apr 1. Leukemia. 2010. PMID: 20357823 No abstract available.
-
After 95 years, it's time to eRASe JMML.Blood Rev. 2020 Sep;43:100652. doi: 10.1016/j.blre.2020.100652. Epub 2020 Jan 16. Blood Rev. 2020. PMID: 31980238 Review.
-
Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.Pediatr Res. 2009 Mar;65(3):334-40. doi: 10.1203/PDR.0b013e3181961d2a. Pediatr Res. 2009. PMID: 19047918
Cited by
-
Current management of juvenile myelomonocytic leukemia and the impact of RAS mutations.Paediatr Drugs. 2012 Jun 1;14(3):157-63. doi: 10.2165/11631360-000000000-00000. Paediatr Drugs. 2012. PMID: 22480363 Review.
-
Chromatin regulator Asxl1 loss and Nf1 haploinsufficiency cooperate to accelerate myeloid malignancy.J Clin Invest. 2018 Dec 3;128(12):5383-5398. doi: 10.1172/JCI121366. Epub 2018 Oct 29. J Clin Invest. 2018. PMID: 30226831 Free PMC article.
-
A case report of acute myeloid leukemia and neurofibromatosis 1.Hematol Rep. 2013 Jul 3;5(2):28-9. doi: 10.4081/hr.2013.e8. Print 2013 Jun 28. Hematol Rep. 2013. PMID: 23888244 Free PMC article.
-
Gene-expression and in vitro function of mesenchymal stromal cells are affected in juvenile myelomonocytic leukemia.Haematologica. 2015 Nov;100(11):1434-41. doi: 10.3324/haematol.2015.126938. Epub 2015 Aug 20. Haematologica. 2015. PMID: 26294732 Free PMC article. Clinical Trial.
-
Decitabine-based treatment strategy improved the outcome of HSCT in JMML: a retrospective cohort study.Front Immunol. 2024 Aug 26;15:1426640. doi: 10.3389/fimmu.2024.1426640. eCollection 2024. Front Immunol. 2024. PMID: 39253078 Free PMC article.
References
-
- Hasle H, Wadsworth LD, Massing BG, McBride M, Schultz KR. A population-based study of childhood myelodysplastic syndrome in British Columbia, Canada. Br J Haematol. 1999;106(4):1027–32. - PubMed
-
- Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Pathology and genetics of Tumours of Haematopoietic and Lymphoid tissues. IARC Press; Lyon: 2001. World Health Organization classification of tumours.
-
- EWOG-MDS. Clinical Trial Protocol EWOG-MDS 2006. Prospective non-randomized multi-center study for epidemiology and characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leukemia (JMML) in childhood. 2007
-
- Niemeyer CM, Arico M, Basso G, Biondi A, Cantu Rajnoldi A, Creutzig U, et al. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS) Blood. 1997;89(10):3534–43. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
